학술논문
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute lymphoblastic leukemia–like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study
Document Type
Article
Author
Lazzarotto, Davide; Tanasi, Ilaria; Vitale, Antonella; Piccini, Matteo; Dargenio, Michelina; Giglio, Fabio; Forghieri, Fabio; Fracchiolla, Nicola; Cerrano, Marco; Todisco, Elisabetta; Papayannidis, Cristina; Leoncin, Matteo; Defina, Marzia; Guolo, Fabio; Pasciolla, Crescenza; Delia, Mario; Chiusolo, Patrizia; Mulè, Antonino; Candoni, Anna; Bonifacio, Massimiliano
Source
Subject
*STEM cell transplantation
*ACUTE leukemia
*ACUTE myeloid leukemia
*LYMPHOBLASTIC leukemia
*RETROSPECTIVE studies
*
*
*
*
Language
ISSN
0939-5555
Abstract
Mixed-phenotype acute leukemia (MPAL) is a rare disease. Treatment is often similar to that of acute lymphoblastic leukemia (ALL), but the outcome in adults and the role of allogeneic stem cell transplantation (AlloSCT) are not well defined. We report on 77 adult patients diagnosed with MPAL over the last 10 years and treated with a curative intent. Median age was 49 years; 7.6% of cases had a BCR::ABL1 rearrangement. Thirty patients (39%) were treated with an acute myeloid leukemia (AML)–like induction and 47 (61%) with an ALL-like scheme. The complete remission (CR) rate was 67.6% and an ALL-like therapy was associated with a better CR rate (P = 0.048). The median OS was 41.9 months; age ≤ 60 years was associated with a better OS (67 vs 26 months, P = 0.014). An AlloSCT was performed in 50 patients (65%). The 5-year OS of transplanted patients was 54%. The OS post-AlloSCT was better in patients who were minimal residual disease (MRD)-negative prior to transplant (75.8% vs 45.2%, P = 0.06). This study shows that MPAL patients respond better to an ALL-like induction therapy; that consolidation therapy should include, whenever possible, an AlloSCT and that MRD negativity should be a primary endpoint of treatment. [ABSTRACT FROM AUTHOR]